Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of “Moderate Buy” by Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $99.6667.

A number of research analysts have weighed in on PVLA shares. HC Wainwright raised their price objective on shares of Palvella Therapeutics from $95.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. TD Cowen boosted their target price on shares of Palvella Therapeutics from $65.00 to $97.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Truist Financial upped their target price on shares of Palvella Therapeutics from $80.00 to $105.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald boosted their price objective on Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $77.85 on Wednesday. The stock has a market capitalization of $861.02 million, a PE ratio of -20.54 and a beta of -0.05. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $83.00. The stock has a 50 day moving average price of $67.15 and a two-hundred day moving average price of $43.73.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, November 11th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Research analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current year.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Archer Investment Corp bought a new position in Palvella Therapeutics during the 3rd quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics during the second quarter valued at about $37,000. JPMorgan Chase & Co. boosted its holdings in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Palvella Therapeutics in the 2nd quarter worth about $85,000. Finally, BNP Paribas Financial Markets bought a new stake in Palvella Therapeutics in the 2nd quarter worth about $104,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.